

Lotilaner: Adis Evaluation

Key Points

- A GABA-Cl inhibitor selective for mites being developed by Tarsus for the treatment of *Demodex* blepharitis and *Demodex*-induced meibomianitis
- Received its first approval on 24 July 2023 in the USA
- Approved for the treatment of *Demodex* blepharitis

Summary

Lotilaner ophthalmic solution 0.25% (XDEMVEY™), a gamma-aminobutyric acid-gated chloride channel (GABA-Cl) inhibitor selective for mites, is being developed by Tarsus Pharmaceuticals for the treatment of *Demodex* blepharitis and meibomian gland dysfunction in patients with *Demodex* lid infestation (Demodex-induced meibomianitis).

On 24 July 2023, lotilaner ophthalmic solution 0.25% received its first approval in the USA for the treatment of *Demodex* blepharitis. The agent is also currently in phase 3 development for *Demodex* blepharitis in China and phase 2 development for *Demodex*-induced meibomianitis in the USA.

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2023.